How can we use Minimal Residual Disease in the treatment of CLL?
Minimal Residual Disease (MRD) has become a popular endpoint to use in chronic lymphocytic leukemia (CLL), as new combinations of drugs can induce outcomes resulting in an undetectable MRD. Thus, Professor in Medical Oncology, Paolo Ghia, emphasizes in this MEDtalk, that even though MRD is highly recommended to use in clinical trials of etc. newly developed drugs in CLL, we lack evidence in the use of MRD in clinical practice setting of patients with CLL.
